loading
Abcellera Biologics Inc stock is traded at $3.01, with a volume of 1.22M. It is down -0.67% in the last 24 hours and down -28.78% over the past month. AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$3.04
Open:
$3.02
24h Volume:
1.22M
Relative Volume:
0.30
Market Cap:
$902.50M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-5.7885
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-2.59%
1M Performance:
-28.78%
6M Performance:
-31.21%
1Y Performance:
-0.34%
1-Day Range:
Value
$2.99
$3.11
1-Week Range:
Value
$2.965
$3.235
52-Week Range:
Value
$1.8906
$6.515

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name
Name
Abcellera Biologics Inc
Name
Phone
(604) 559-9005
Name
Address
150 W 4TH AVENUE, VANCOUVER
Name
Employee
596
Name
Twitter
Name
Next Earnings Date
2024-11-18
Name
Latest SEC Filings
Name
ABCL's Discussions on Twitter

Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ABCL
Abcellera Biologics Inc
3.015 909.98M 38.03M -146.40M -121.38M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
485.80 121.15B 12.07B 3.95B 3.19B 15.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
785.38 82.43B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
829.66 52.25B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.60 44.59B 3.71B 313.75M 465.38M 2.2571
Biotechnology icon
ONC
Beone Medicines Ltd Adr
366.48 40.07B 4.98B 69.60M 525.67M 0.5198

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jul-07-25 Resumed Leerink Partners Outperform
Aug-20-24 Downgrade The Benchmark Company Buy → Hold
Feb-22-24 Upgrade The Benchmark Company Hold → Buy
Dec-05-23 Initiated KeyBanc Capital Markets Overweight
Nov-06-23 Downgrade The Benchmark Company Buy → Hold
Oct-13-23 Resumed Piper Sandler Overweight
Feb-28-23 Initiated Cowen Outperform
Dec-15-22 Initiated Goldman Buy
Nov-16-22 Initiated Truist Buy
Dec-21-21 Initiated The Benchmark Company Buy
Nov-19-21 Initiated Piper Sandler Overweight
Jan-05-21 Initiated BMO Capital Markets Outperform
Jan-05-21 Initiated Berenberg Buy
Jan-05-21 Initiated Credit Suisse Outperform
Jan-05-21 Initiated SVB Leerink Outperform
Jan-05-21 Initiated Stifel Buy
View All

Abcellera Biologics Inc Stock (ABCL) Latest News

pulisher
09:46 AM

AbCellera Biologics Inc (ABCL) Misses Q4 2025 Earnings Estimates — EPS $-0.19 vs $-0.16 Expected - AlphaStreet News

09:46 AM
pulisher
Feb 22, 2026

AbCellera Biologics Faces Stock Volatility Amid Strategic Decisions - timothysykes.com

Feb 22, 2026
pulisher
Feb 21, 2026

AbCellera Biologics Inc (ABCL) down 23% since Q3 2025 results - MSN

Feb 21, 2026
pulisher
Feb 21, 2026

Is AbCellera Biologics Inc affected by consumer sentimentJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn

Feb 21, 2026
pulisher
Feb 18, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Feb 18, 2026
pulisher
Feb 17, 2026

AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday - MarketBeat

Feb 17, 2026
pulisher
Feb 15, 2026

Aug Mood: Is AbCellera Biologics Inc a potential multi baggerJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn

Feb 15, 2026
pulisher
Feb 14, 2026

AbCellera Biologics (NASDAQ:ABCL) Upgraded by Wall Street Zen to Hold Rating - MarketBeat

Feb 14, 2026
pulisher
Feb 13, 2026

AbCellera Biologics (NASDAQ:ABCL) Trading Up 8.3%Still a Buy? - MarketBeat

Feb 13, 2026
pulisher
Feb 13, 2026

AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech With A 234% Potential Upside - DirectorsTalk Interviews

Feb 13, 2026
pulisher
Feb 12, 2026

How resilient is AbCellera Biologics Inc. stock in market downturnsJuly 2025 Weekly Recap & Daily Entry Point Alerts - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

State of Michigan Retirement System Acquires 350,775 Shares of AbCellera Biologics Inc. $ABCL - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Is AbCellera’s Biotech Platform Setting New Standards for Pharmaceutical Innovation - Kalkine Media

Feb 12, 2026
pulisher
Feb 11, 2026

Painful Week for Individual Investors Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) After 10% Drop, Institutions Also Suffered Losses - 富途牛牛

Feb 11, 2026
pulisher
Feb 11, 2026

Travel Stocks: Is Lifeway Foods Inc forming a double bottom2025 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn

Feb 11, 2026
pulisher
Feb 11, 2026

AbCellera to Present at Upcoming Investor Conferences in March and April 2026 - Investing News Network

Feb 11, 2026
pulisher
Feb 11, 2026

How AbCellera Biologics Inc. stock trades before earnings2025 Earnings Surprises & Stock Timing and Entry Methods - mfd.ru

Feb 11, 2026
pulisher
Feb 05, 2026

Is AbCellera (ABCL) Trading Its Platform Identity For Higher-Stakes Clinical Ambitions? - Sahm

Feb 05, 2026
pulisher
Feb 05, 2026

Short sales on the TSX: What bearish investors are betting against - The Globe and Mail

Feb 05, 2026
pulisher
Feb 04, 2026

Will AbCellera Biologics Inc. stock maintain growth story2025 Pullback Review & Long-Term Growth Stock Strategies - mfd.ru

Feb 04, 2026
pulisher
Feb 03, 2026

OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha

Feb 03, 2026
pulisher
Feb 02, 2026

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey

Feb 02, 2026
pulisher
Feb 02, 2026

What does Wall Street think about AbCellera Biologics Inc. (ABCL)? - MSN

Feb 02, 2026
pulisher
Jan 31, 2026

AbCellera’s ABCL635 Phase 2 Start Highlights Menopause Focus And Valuation Gap - Yahoo Finance

Jan 31, 2026
pulisher
Jan 30, 2026

AbCellera Biologics (ABCL) Valuation Check After Mixed Long Term Shareholder Returns - Yahoo Finance

Jan 30, 2026
pulisher
Jan 30, 2026

AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets - Sahm

Jan 30, 2026
pulisher
Jan 30, 2026

Reassessing AbCellera Biologics (ABCL) After A Sharp 16.8% Weekly Share Price Drop - Yahoo Finance

Jan 30, 2026
pulisher
Jan 29, 2026

What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? - Insider Monkey

Jan 29, 2026
pulisher
Jan 26, 2026

Exit Recap: Why is AbCellera Biologics Inc stock going downJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 26, 2026

Can AbCellera Biologics Inc disrupt its industry2025 Winners & Losers & Free High Return Stock Watch Alerts - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 25, 2026

Strategic Moves Shape ABCL’s Market Position - StocksToTrade

Jan 25, 2026
pulisher
Jan 25, 2026

AbCellera’s Market Moves: Key Developments - timothysykes.com

Jan 25, 2026
pulisher
Jan 24, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Rating of "Hold" by Brokerages - MarketBeat

Jan 24, 2026
pulisher
Jan 23, 2026

AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1%Here's Why - MarketBeat

Jan 23, 2026
pulisher
Jan 23, 2026

Is AbCellera Biologics Inc a top pick in the sectorPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 23, 2026

AbCellera Biologics Inc. (ABCL) Stock Analysis: Exploring a Promising 111.93% Potential Upside - DirectorsTalk Interviews

Jan 23, 2026
pulisher
Jan 22, 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 - PharmiWeb.com

Jan 22, 2026
pulisher
Jan 22, 2026

AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6%Here's Why - MarketBeat

Jan 22, 2026
pulisher
Jan 22, 2026

A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Advances Into Phase 2 Trial - Sahm

Jan 22, 2026
pulisher
Jan 20, 2026

AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen - MarketBeat

Jan 20, 2026
pulisher
Jan 18, 2026

Why AbCellera Biologics Inc. stock could rally in 2025High Dividend Yield Stocks & Invest Like A Pro - bollywoodhelpline.com

Jan 18, 2026
pulisher
Jan 16, 2026

Is AbCellera (ABCL) Quietly Recasting Its Platform As A Menopause-Focused Drug Developer? - simplywall.st

Jan 16, 2026
pulisher
Jan 15, 2026

Aug Reactions: What is the implied volatility of Sonida Senior Living IncMarket Movers & Weekly Hot Stock Watchlists - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 15, 2026

Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL - MarketBeat

Jan 15, 2026
pulisher
Jan 14, 2026

AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 - Yahoo Finance

Jan 14, 2026
pulisher
Jan 14, 2026

AbCellera Biologics Inc Doses First Patients in Phase 2 Trial for ABCL635 - TradingView — Track All Markets

Jan 14, 2026
pulisher
Jan 14, 2026

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Investing News Network

Jan 14, 2026
pulisher
Jan 13, 2026

AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.6%Should You Sell? - MarketBeat

Jan 13, 2026
pulisher
Jan 13, 2026

AbCellera begins phase 2 trial of non-hormonal menopause treatment By Investing.com - Investing.com Nigeria

Jan 13, 2026
pulisher
Jan 13, 2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause - BioSpace

Jan 13, 2026
pulisher
Jan 12, 2026

AbCellera begins phase 2 trial of non-hormonal menopause treatment - Investing.com

Jan 12, 2026

Abcellera Biologics Inc Stock (ABCL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$101.66
price down icon 0.09%
$50.51
price up icon 1.10%
$100.35
price down icon 0.96%
$109.15
price down icon 1.00%
$160.30
price down icon 2.59%
biotechnology ONC
$366.08
price up icon 0.93%
Cap:     |  Volume (24h):